Clinical trials: Lung; Disease, Interstitial, With Fibrosis
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Pulmonary Fibrosis
Lung Disease Associated With Rheumatoid Arthritis
Pulmonary fibrosis (PF) is a condition in which the lungs of a patient become scarred and fibrous. It has been known to occur in as many as 40% of patients diagnosed with rheumatoid arthritis (RA).
- Trial name
- NCT00001876
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Idiopathic Pulmonary Fibrosis
NAL ER IPF Respiratory Function and Safety Study
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
- Trial name
- NCT07036029
- Testing
- NAL ER
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Trevi Therapeutics
Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease
Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients With Cystic Fibrosis, Pulmonary Fibrosis or COPD (Chronic Obstructive Pulmonary Disease)
The main objective of the study is to assess the potential of time-frequency representation and analysis of pulmonary sounds collected with an electronic stethoscope, as part of the routine monitoring of patients with cystic…
- Conditions
- Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis
- Trial name
- ATF/SPP (NCT06399094)
- Testing
- Lung sound recordings
- Where
- 2 sites in France
- Volunteers
- 23 people
- Sponsor
- Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Idiopathic Pulmonary Fibrosis
Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis
This study measures the 4 metre gait speed (4MGS) test in patients with Idiopathic Pulmonary Fibrosis (IPF). The investigators are interested to see whether usual walking speed in IPF patients changes following pulmonary…
- Trial name
- IPFRESP (NCT02530736)
- Testing
- 4 metre gait speed
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis (IPF)
Downhill Walking in IPF
In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF.
- Trial name
- NCT06756230
- Testing
- Pulmonary Rehabilitation, Downhill Walking, Treadmill Walking without incline
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Saglik Bilimleri Universitesi
Pulmonary Fibrosis, Breast Cancer
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
Two hundred and sixty patients with breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms.
- Trial name
- CONSET (NCT00896155)
- Testing
- Tamoxifen, Radiotherapy
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Hospital
Idiopathic Pulmonary Fibrosis
D2212C00002 J-Phase II Study
The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT02036580
- Testing
- tralokinumab cohort 1, tralokinumab cohort 2
- Where
- 5 sites in Japan
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of…
- Trial name
- NCT04968574
- Testing
- taladegib
- Where
- 24 sites in Australia, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Endeavor Biomedicines, Inc.
Healthy Participants
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
- Trial name
- NCT05684289
- Testing
- BMS-986278, Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis, Hypoxemia
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
- Trial name
- NCT02846324
- Testing
- GBT440
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Global Blood Therapeutics
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor…
- Trial name
- NCT00074698
- Testing
- FG-3019
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kyntra Bio
Chronic Obstructive Pulmonary Disease, Asthma
Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
The first-in-man study are designed as below to assess safety, tolerability, and preliminary pharmacokinetics of ZL-2102. Double-blind randomized, placebo-controlled ascending single oral doses (Part 1, ZL-2102-SAD); Open-label…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02397005
- Testing
- ZL-2102
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Zai Lab Pty. Ltd.
Idiopathic Pulmonary Fibrosis
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients…
- Trial name
- NCT04614441
- Testing
- OFEV®
- Where
- 26 sites in Taiwan
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT06967805
- Testing
- MTX-463
- Where
- 59 sites in United States, Argentina and 9 more
- Volunteers
- 168 people
- Sponsor
- Mediar Therapeutics
Idiopathic Pulmonary Fibrosis, Lung; Disease, Interstitial, With Fibrosis
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
This is a phase 1, randomized, First in Human (FIH), double-blinded, placebo-controlled study to assess the safety, tolerability, and PK of RSN0402 in healthy volunteers.
- Trial name
- NCT06482190
- Testing
- RSN0402 Part 1, RSN0402 Part 2
- Where
- 3 sites in Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenzhen Resproly Biopharmaceutical Co., Ltd
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
This study is meant to compare the amount of oxygen required for hypoxemia relief between current standard of care (oxygen only) and oxygen with the addition of high flow air for Chronic Obstructive Pulmonary Disease (COPD)…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Pulmonary Fibrosis, Hypoxemia
- Trial name
- NCT04170062
- Testing
- Nasal Delivery of High-Flow Air and Oxygen Therapy, Nasal Delivery of Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Johns Hopkins University
Fibrosing Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis
Yoga in Patients With Fibrosing Interstitial Lung Diseases
Fibrosing interstitial lung diseases are characterized by loss of lung function, which leads to a decrease in quality of life and physical capacity.
- Trial name
- NCT03979703
- Testing
- 12 week yoga class
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Heidelberg University
Pulmonary Fibrosis
SVF for Treating Pulmonary Fibrosis Post COVID-19
General description of the study This is a prospective, multicenter, expanded access interventional study of subjects recovered from COVID-19 pneumonia to assess their response to intravenous administration of adipose-derived…
- Trial name
- SVFCOVID-19 (NCT06304623)
- Testing
- Autologous adipose-derived SVF IV administration
- Where
- 2 sites in Nicaragua
- Volunteers
- 40 people
- Sponsor
- Michael H Carstens
Idiopathic Pulmonary Fibrosis
Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis
Clinical Trial Phase I, open, multicentric, non randomized, study with escalating doses, to evaluate the safety and feasibility of treatment with mesenchymal stem cells in patients with diagnosis of idiopathic pulmonary fibrosis.
- Trial name
- CMM/FPI (NCT01919827)
- Testing
- Endobronchial infusion of adult mesenchymal stem cells, Autologous mesenchymal stem cells derived from bone marrow
- Where
- 2 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra